Contrarily, in the AMLSG 07-04 trial, adding ATRA to standard induction therapy in younger adults (18–60 years) with NPM1-mutated/FLT3-ITD-negative AML led to improved EFS and OS [141]. Here, NPM1 is linked to acute myeloid leukemia.